文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

接受异基因移植的血液系统恶性肿瘤患者的医疗费用:美国支付方视角

Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective.
PubMed 文献 · Blood Adv · 2024-01-01

基于美国商业保险数据库(2016年第一季度至2020年第二季度),分析1082例接受住院异基因造血细胞移植的血液系统恶性肿瘤患者,从移植前100天至移植后100天评估医疗资源使用与费用。移植后100天内52%发生急性移植物抗宿主病,21%发生巨细胞病毒感染;非按人头付费计划患者(n=937)移植期间每例全因医疗费用中位数为331827美元。缩短原发住院时长和避免再入院应能显著降低移植医疗费用。

要点

  • 移植后100天内52%患者发生急性移植物抗宿主病,21%发生巨细胞病毒感染。
  • 原发住院中位时长28天,31%患者在移植后100天内需要再入院。
  • 非按人头付费计划患者移植期间每例全因医疗费用中位数为331827美元。

核心结论

  • 缩短原发住院时长和避免再入院应能显著降低异基因造血细胞移植的医疗费用。

研究设计与样本

  • 使用Merative MarketScan商业索赔与 encounters 数据库(2016年第一季度至2020年第二季度)的回顾性分析。
  • 纳入1082例年龄12至64岁、诊断为血液系统恶性肿瘤并接受住院异基因造血细胞移植的美国商业保险患者。
  • 从移植前100天至移植后100天评估医疗资源使用与费用,并发症发生率基于移植日至移植后100天的医疗账单代码评估。

主要发现

  • 移植移植物来源包括外周血79%、骨髓11%和脐带血3%。
  • 移植后100天内52%患者发生急性移植物抗宿主病,21%发生巨细胞病毒感染。
  • 原发住院中位时长为28天,31%患者在移植后100天内需要再入院。
  • 移植期间(移植前14天至移植后100天)44%患者入住重症监护室,中位时长为29天。
  • 非按人头付费计划患者(n=937)移植期间每例全因医疗费用中位数为331827美元,主要由原发住院和再入院驱动。

关键数值与推荐

  • 住院时长每增加一天,预测的中位增量费用随住院时长延长而增加,例如第10至20天为3381至4071美元。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) require extensive care. Using the Merative MarketScan Commercial Claims and Encounters database (2016 Q1-2020 Q2), we quantified the costs of care and assessed real-world complication rates among commercially insured US patients diagnosed with a hematologic malignancy and aged between 12 and 64 years undergoing inpatient allo-HCT. Health care resource use and costs were assessed from 100 days before HCT to 100 days after HCT. Primary hospitalization was defined as the time from HCT until first discharge date. Incidence of complications was assessed using medical billing codes from HCT date to 100 days after HCT. Among the 1082 patients analyzed, allo-HCT grafts included peripheral blood (79%), bone marrow (11%), and umbilical cord blood (3%). In the 100 days after HCT, 52% of the patients experienced acute graft-versus-host disease; 21% had cytomegalovirus infection. The median primary hospitalization length of stay (LOS) was 28 days; 31% required readmission in first 100 days after HCT. Across the transplant period (14 days pretransplant to 100 days posttransplant), 44% of patients were admitted to the intensive care unit with a median LOS of 29 days. Among those with noncapitated health plans (n = 937), median cost of all-cause health care per patient during the transplant period was $331 827, which was driven by primary hospitalization and readmission. Additionally, the predicted median incremental costs per additional day in an inpatient setting increased with longer LOS (eg, $3381-$4071, 10th-20th day.) Thus, decreasing length of primary hospitalization and avoiding readmissions should significantly reduce the allo-HCT cost of care.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Maziarz RT, Gergis U, Edwards ML, et al. Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective. Blood Adv. 2024. PMID: 38055922. doi:10.1182/bloodadvances.2023011033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。